Literature DB >> 25515714

Cumulative effect of IFIH1 variants and increased gene expression associated with type 1 diabetes.

Magdalena Zurawek1, Marta Fichna2, Piotr Fichna3, Bogda Skowronska3, Agnieszka Dzikiewicz-Krawczyk4, Danuta Januszkiewicz5, Jerzy Nowak4.   

Abstract

AIMS: IFIH1 (Interferon Induced with Helicase C domain 1) gene encodes a sensor of double-stranded RNA, which initiates antiviral activity. Recent studies have indicated the association of rare and common IFIH1 variants with type 1 diabetes mellitus (T1D). The aim of this study was to investigate whether polymorphisms in the IFIH1 locus are a risk factor for T1D in Caucasian patients from Poland.
METHODS: We genotyped 514 T1D patients and 713 healthy control individuals for rs3747517, rs1990760, rs2111485 and rs13422767 variants. Cumulative genetic risk score (CGRS) was calculated using unweighted and weighted approaches. We also examined the expression of IFIH1 gene in a cohort of 90 T1D patients.
RESULTS: All studied polymorphisms showed significant association with type 1 diabetes. The risk alleles G of rs3747517, rs2111485, rs13422767 and A of rs1990760 were observed more frequently in T1D group with P values and allelic odds ratio OR (95%CI) < 0.0001, 1.742 (1.428-2.126); 0.001, 1.336 (1.125-1.588); < 0.0001, 1.799 (1.416-2.285); 0.0005, 1.359 (1.144-1.616), respectively. The risk for type 1 diabetes increased with the growing number of the risk alleles. OR (95%CI) for carriers of ≥ 6 risk alleles reached 2.387 (1.552-3.670) for unweighted CGRS and 3.132 (1.928-5.089) for weighted CGRS. Furthermore, IFIH1 gene expression levels in unstimulated peripheral blood mononuclear cells of T1D patients were significantly higher compared to healthy individuals (mean ± SEM mRNA copy number 163.8 ± 15.7 vs. 117.8 ± 7.2; P = 0.046).
CONCLUSIONS: This study confirms the association of the IFIH1 locus with susceptibility to T1D in the Polish population. The cumulative effect of rs3747517, rs1990760, rs2111485 and rs13422767 variants on type 1 diabetes risk was observed.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Cumulative effect of variants; Gene expression; IFIH1; T1D; Variants

Mesh:

Substances:

Year:  2014        PMID: 25515714     DOI: 10.1016/j.diabres.2014.11.008

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


  6 in total

Review 1.  Discrimination of cytosolic self and non-self RNA by RIG-I-like receptors.

Authors:  Charlotte Lässig; Karl-Peter Hopfner
Journal:  J Biol Chem       Date:  2017-04-14       Impact factor: 5.157

Review 2.  Functional Impact of Risk Gene Variants on the Autoimmune Responses in Type 1 Diabetes.

Authors:  Chelsea Gootjes; Jaap Jan Zwaginga; Bart O Roep; Tatjana Nikolic
Journal:  Front Immunol       Date:  2022-05-04       Impact factor: 8.786

Review 3.  Effects of type 1 diabetes-associated IFIH1 polymorphisms on MDA5 function and expression.

Authors:  Benjamin M Looney; Chang-Qing Xia; Patrick Concannon; David A Ostrov; Michael J Clare-Salzler
Journal:  Curr Diab Rep       Date:  2015-11       Impact factor: 4.810

4.  Genetic variants in ATM, H2AFX and MRE11 genes and susceptibility to breast cancer in the polish population.

Authors:  Marta Podralska; Iwona Ziółkowska-Suchanek; Magdalena Żurawek; Agnieszka Dzikiewicz-Krawczyk; Ryszard Słomski; Jerzy Nowak; Agnieszka Stembalska; Karolina Pesz; Maria Mosor
Journal:  BMC Cancer       Date:  2018-04-20       Impact factor: 4.430

Review 5.  Genetic Susceptibility of the Host in Virus-Induced Diabetes.

Authors:  Keiichiro Mine; Yasunobu Yoshikai; Hirokazu Takahashi; Hitoe Mori; Keizo Anzai; Seiho Nagafuchi
Journal:  Microorganisms       Date:  2020-07-27

Review 6.  Advances in Knowledge of Candidate Genes Acting at the Beta-Cell Level in the Pathogenesis of T1DM.

Authors:  Haipeng Pang; Shuoming Luo; Gan Huang; Ying Xia; Zhiguo Xie; Zhiguang Zhou
Journal:  Front Endocrinol (Lausanne)       Date:  2020-03-12       Impact factor: 5.555

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.